By Connor Hart
Vaxart appointed Jeroen Grasman as its chief financial officer, effective May 19.
Grasman will succeed Phillip Lee, who is resigning from the top finance position for personal reasons, the clinical-stage biotechnology company said Tuesday.
Lee will remain with the company as a non-executive employee through June 1 in order to assist with the transition.
Grasman has more than 20 years of financial leadership experience in the biotechnology industry, Vaxart said. He most recently served as CFO of AltruBio, a private clinical-stage biotech company. Prior, he held leadership roles at PACT Pharma and Intarcia Therapeutics.
Vaxart disclosed the CFO succession as it posted a net loss of $15.6 million, or 7 cents a share in the first quarter, compared with a loss of $24.4 million, or 14 cents a share, a year earlier.
Revenue increased to $20.9 million from $2.2 million.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
May 13, 2025 16:21 ET (20:21 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.